NCT05318027Active, not recruitingPhase 2
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Use of Natural Language Processing ChatBot and Automated Continuous Activity Monitoring Via Mobile Phones for Early Detection and Management of Symptoms in Patients Undergoing Cancer Treatment
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 6 Dec 2021
- Start date
- 22 May 2023
- Primary completion date
- Dec 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Head and neck cancer, Lung cancer
- NCT number
- NCT05318027
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From 22 May 2023 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who are bed bound at baseline (ECOG 4)
- Patients who rely on a wheelchair for ambulation
Who the study is looking for
- Adults (age \>18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
- Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
- Ability read and respond in English
- Ability to provide informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
Related publications
- Digital symptom monitoring and activity tracking in chemoradiation-lessons from the CAM experience.ESMO Real World Data Digit Oncol · 2026 · PMID 41930312
This page is information, not medical advice. Discuss any trial with your doctor.